SALL4 immunoreactivity predicts prognosis in western hepatocellular carcinoma patients but is a rare event: A study of 236 cases

American Journal of Surgical Pathology

Volumn 38, Issue 7, 2014, Pages 966-972

  Liu, Ta Chiang ^a   Vachharajani, Neeta ^a   Chapman, William C ^a   Brunt, Elizabeth M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; immunostain; recurrence; stem cell; survival; transplantation

Indexed keywords

SALL4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CELL DIFFERENTIATION; CHEMISTRY; DISEASE FREE SURVIVAL; ETHNOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; RISK FACTOR; TIME; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR INVASION; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MISSOURI; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84902549483     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000218     Document Type: Article

References (52)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362: 1907-1917.
2. Bruix J, Boix L, Sala M, et al. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5: 215-219.
3. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48(suppl 1):S20-S37.
4. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009;373: 614-616.
5. Bruix J, Llovet JM. Two decades of advances in hepatocellular carcinoma research. Semin Liver Dis. 2010;30: 1-2.
6. Sherman M. Hepatocellular carcinoma: screening and staging. Clin Liver Dis. 2011;15: 323-334.
7. Varela M, Sala M, Llovet JM, et al. Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2003;17(suppl 2): 98-102.
8. Wurmbach E, Chen YB, Khitrov G, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 2007;45: 938-947.
9. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51: 1820-1832.
10. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53: 1020-1022.
11. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48: 1312-1327.
12. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359: 378-390.
13. Newell P, Toffanin S, Villanueva A, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 2009;51: 725-733.
14. Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology. 2006;131: 1758-1767.
15. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359: 1995-2004.
16. Tovar V, Alsinet C, Villanueva A, et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol. 2010;52: 550-559.
17. Villanueva A, Hoshida Y, Battiston C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011;140:1501-1512 e1502.
18. Oliva J, French BA, Qing X, et al. The identification of stem cells in human liver diseases and hepatocellular carcinoma. Exp Mol Pathol. 2010;88: 331-340.
19. Yeh CT, Kuo CJ, Lai MW, et al. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer. 2009;9:324.
20. Machida K, Chen CL, Liu JC, et al. Cancer stem cells generated by alcohol, diabetes, and hepatitis C virus. J Gastroenterol Hepatol. 2012;27(suppl 2): 19-22.
21. Marquardt JU, Raggi C, Andersen JB, et al. Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology. 2011;54: 1031-1042.
22. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12: 410-416.
23. Uenishi T, Kubo S, Yamamoto T, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003;94: 851-857.
24. Yang XR, Xu Y, Shi GM, et al. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res. 2008;14: 3850-3859.
25. Ma Y, Cui W, Yang J, et al. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood. 2006;108: 2726-2735.
26. Cui W, Kong NR, Ma Y, et al. Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia. Mod Pathol. 2006;19: 1585-1592.
27. Cao D, Li J, Guo CC, et al. SALL4 is a novel diagnostic marker for testicular germ cell tumors. Am J Surg Pathol. 2009;33: 1065-1077.
28. Oikawa T, Kamiya A, Zeniya M, et al. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology. 2013;57: 1469-1483.
29. Yong KJ, Gao C, Lim JS, et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med. 2013;368: 2266-2276.
30. Cao D, Guo S, Allan RW, et al. SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. Am J Surg Pathol. 2009;33: 894-904.
31. Fujii Y, Yoshihashi K, Suzuki H, et al. CDX1 confers intestinal phenotype on gastric epithelial cells via induction of stemnessassociated reprogramming factors SALL4 and KLF5. Proc Natl Acad Sci USA. 2012;109: 20584-20589.
32. Yang J, Chai L, Liu F, et al. Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci USA. 2007; 104: 10494-10499.
33. Yang J, Chai L, Gao C, et al. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood. 2008;112: 805-813.
34. Kobayashi D, Kuribayshi K, Tanaka M, et al. SALL4 is essential for cancer cell proliferation and is overexpressed at early clinical stages in breast cancer. Int J Oncol. 2011;38: 933-939.
35. Kobayashi D, Kuribayashi K, Tanaka M, et al. Overexpression of SALL4 in lung cancer and its importance in cell proliferation. Oncol Rep. 2011;26: 965-970.
36. Ushiku T, Shinozaki A, Shibahara J, et al. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am J Surg Pathol. 2010;34: 533-540.
37. Ikeda H, Sato Y, Yoneda N, et al. alpha-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression. Hum Pathol. 2012;43: 1955-1963.
38. Mei K, Liu A, Allan RW, et al. Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system: a study of 77 cases. Mod Pathol. 2009;22: 1628-1636.
39. Wang B, Li L, Ni F, et al. Mutational analysis of SAL-Like 4 (SALL4) in Han Chinese women with premature ovarian failure. Mol Hum Reprod. 2009;15: 557-562.
40. Wang F, Liu A, Peng Y, et al. Diagnostic utility of SALL4 in extragonadal yolk sac tumors: an immunohistochemical study of 59 cases with comparison to placental-like alkaline phosphatase, alphafetoprotein, and glypican-3. Am J Surg Pathol. 2009;33: 1529-1539.
41. Cao D, Humphrey PA, Allan RW. SALL4 is a novel sensitive and specific marker for metastatic germ cell tumors, with particular utility in detection of metastatic yolk sac tumors. Cancer. 2009;115: 2640-2651.
42. Arzumanyan A, Friedman T, Ng IO, et al. Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells? Cancer Res. 2011;71: 3701-3708.
43. Wang C, Yang W, Yan HX, et al. Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3, 5-diethoxycarbonyl- 1, 4-dihydrocollidine-treated HBx transgenic mice. Hepatology. 2012;55: 108-120.
44. Huang J, Shen L, Lu Y, et al. Parallel induction of cell proliferation and inhibition of cell differentiation in hepatic progenitor cells by hepatitis B virus X gene. Int J Mol Med. 2012;30: 842-848.
45. Yoon SM, Gerasimidou D, Kuwahara R, et al. Epithelial cell adhesion molecule (EpCAM) marks hepatocytes newly derived from stem/progenitor cells in humans. Hepatology. 2011;53: 964-973.
46. Feng D, Kong X, Weng H, et al. Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology. 2012;143:188-198 e187.
47. Sun YL, Yin SY, Xie HY, et al. Stem-like cells in hepatitis B virusassociated cirrhotic livers and adjacent tissue to hepatocellular carcinomas possess the capacity of tumorigenicity. J Gastroenterol Hepatol. 2008;23: 1280-1286.
48. Ali N, Allam H, May R, et al. Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts. J Virol. 2011;85: 12292-12303.
49. Ziol M, Nault JC, Aout M, et al. Intermediate hepatobiliary cells predict an increased risk of hepatocarcinogenesis in patients with hepatitis C virus-related cirrhosis. Gastroenterology. 2010;139: 335-343 e332.
50. Pereira Tde A, Witek RP, Syn WK, et al. Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Lab Invest. 2010;90: 1690-1703.
51. Machida K, Tsukamoto H, Mkrtchyan H, et al. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci USA. 2009;106: 1548-1553.
52. Machida K. TLRs, alcohol, HCV, and tumorigenesis. Gastroenterol Res Pract. 2010;2010:518674.